172P Insights into male breast cancer: A 35-year mono-institutional retrospective study on adjuvant radiotherapy (RT)
Carlo Alberto Giorgi(Istituto Oncologico Veneto), V. Guarneri(University of Padua), Federica Miglietta(University of Padua), Sara Talomo(Istituto Oncologico Veneto), E. Bovo(Istituto Oncologico Veneto), Alessandro Parisi(Marche Polytechnic University), F. Pasqualetti(University of Padua), Luisa Bellu(Sorbonne Université), Francesca Porra(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Massimo Ferrucci(Istituto Oncologico Veneto), Giovanni Faggioni(Istituto Oncologico Veneto), Federica Guida(Istituto Oncologico Veneto), Maria Vittoria Dieci(Istituto Oncologico Veneto), F. Busato(Istituto Oncologico Veneto), Eleonora Mioranza(Istituti di Ricovero e Cura a Carattere Scientifico), Cristina Falci(Istituti di Ricovero e Cura a Carattere Scientifico), M. Krengli(University of Padua)
Cited by 0
Related Papers
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
|JNCI Journal of the National Cancer Institute|2019|168
The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
|Cancer Treatment Reviews|2016|128